Genetic Technologies (NASDAQ:GENE) Shares Up 2.2%

Genetic Technologies Limited (NASDAQ:GENE) shares shot up 2.2% during trading on Monday . The company traded as high as $2.85 and last traded at $2.29, 75,697 shares traded hands during mid-day trading. A decline of 30% from the average session volume of 108,662 shares. The stock had previously closed at $2.24.

Separately, ValuEngine downgraded Genetic Technologies from a “buy” rating to a “hold” rating in a report on Monday, May 13th.

The business has a fifty day moving average price of $1.01 and a 200 day moving average price of $0.85.

An institutional investor recently bought a new position in Genetic Technologies stock. Alpine Group USVI LLC acquired a new stake in Genetic Technologies Limited (NASDAQ:GENE) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 28,437 shares of the biotechnology company’s stock, valued at approximately $25,000. Genetic Technologies comprises 0.1% of Alpine Group USVI LLC’s portfolio, making the stock its 15th biggest position. Alpine Group USVI LLC owned about 0.18% of Genetic Technologies at the end of the most recent reporting period. Institutional investors and hedge funds own 4.16% of the company’s stock.

Genetic Technologies Company Profile (NASDAQ:GENE)

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.

Featured Article: Why is cost of goods sold important?

Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit